Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 2
2007 3
2008 3
2009 3
2010 7
2011 5
2012 5
2013 9
2014 6
2015 5
2016 9
2017 10
2018 10
2019 28
2020 16
2021 27
2022 18
2023 21
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Results by year

Filters applied: . Clear all
Page 1
Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients.
Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, Yefet LS, Tonn JC, Gui C, Ostrom QT, Barnholtz-Sloan J, Perry A, Ellenbogen Y, Hanemann CO, Jungwirth G, Jenkinson MD, Tabatabai G, Mathiesen TI, McDermott MW, Tatagiba M, la Fougère C, Maas SLN, Galldiks N, Albert NL, Brastianos PK, Ehret F, Minniti G, Lamszus K, Ricklefs FL, Schittenhelm J, Drummond KJ, Dunn IF, Pathmanaban ON, Cohen-Gadol A, Sulman EP, Tabouret E, Le Rhun E, Mawrin C, Moliterno J, Weller M, Bi WL, Gao A, Yip S, Niyazi M; International Consortium on Meningiomas (ICOM); Aldape K, Wen PY, Short S, Preusser M, Nassiri F, Zadeh G. Wang JZ, et al. Among authors: tabatabai g. Neuro Oncol. 2024 May 2:noae082. doi: 10.1093/neuonc/noae082. Online ahead of print. Neuro Oncol. 2024. PMID: 38695575
Preoperative growth dynamics of untreated glioblastoma: Description of an exponential growth type, correlating factors, and association with postoperative survival.
Feucht D, Haas P, Skardelly M, Behling F, Rieger D, Bombach P, Paulsen F, Hoffmann E, Hauser TK, Bender B, Renovanz M, Niyazi M, Tabatabai G, Tatagiba M, Roder C. Feucht D, et al. Among authors: tabatabai g. Neurooncol Adv. 2024 Apr 3;6(1):vdae053. doi: 10.1093/noajnl/vdae053. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38680987 Free PMC article.
Functionally-instructed modifiers of response to ATR inhibition in experimental glioma.
Walter B, Hirsch S, Kuhlburger L, Stahl A, Schnabel L, Wisser S, Haeusser LA, Tsiami F, Plöger S, Aghaallaei N, Dick AM, Skokowa J, Schmees C, Templin M, Schenke-Layland K, Tatagiba M, Nahnsen S, Merk DJ, Tabatabai G. Walter B, et al. Among authors: tabatabai g. J Exp Clin Cancer Res. 2024 Mar 12;43(1):77. doi: 10.1186/s13046-024-02995-z. J Exp Clin Cancer Res. 2024. PMID: 38475864 Free PMC article.
[Neuro-oncology: challenges and perspectives].
Tabatabai G, Schlegel U. Tabatabai G, et al. Nervenarzt. 2024 Feb;95(2):93-95. doi: 10.1007/s00115-023-01603-3. Epub 2024 Feb 7. Nervenarzt. 2024. PMID: 38324029 Free PMC article. German. No abstract available.
Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12).
Bodensohn R, Fleischmann DF, Maier SH, Anagnostatou V, Garny S, Nitschmann A, Büttner M, Mücke J, Schönecker S, Unger K, Hoffmann E, Paulsen F, Thorwarth D, Holzgreve A, Albert NL, Corradini S, Tabatabai G, Belka C, Niyazi M. Bodensohn R, et al. Among authors: tabatabai g. Clin Transl Radiat Oncol. 2023 Dec 3;45:100706. doi: 10.1016/j.ctro.2023.100706. eCollection 2024 Mar. Clin Transl Radiat Oncol. 2023. PMID: 38116137 Free PMC article.
Concurrent gliomas in patients with multiple sclerosis.
Sahm K, Kessler T, Eisele P, Ratliff M, Sperk E, König L, Breckwoldt MO, Seliger C, Mildenberger I, Schrimpf D, Herold-Mende C, Zeiner PS, Tabatabai G, Meuth SG, Capper D, Bendszus M, von Deimling A, Wick W, Sahm F, Platten M. Sahm K, et al. Among authors: tabatabai g. Commun Med (Lond). 2023 Dec 18;3(1):186. doi: 10.1038/s43856-023-00381-y. Commun Med (Lond). 2023. PMID: 38110626 Free PMC article.
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. Zeyen T, et al. Among authors: tabatabai g. J Neurooncol. 2023 Nov;165(2):387. doi: 10.1007/s11060-023-04488-z. J Neurooncol. 2023. PMID: 37921974 Free PMC article. No abstract available.
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Grassl N, Sahm K, Süße H, Poschke I, Bunse L, Bunse T, Boschert T, Mildenberger I, Rupp AK, Ewinger MP, Lanz LM, Denk M, Tabatabai G, Ronellenfitsch MW, Herrlinger U, Glas M, Krex D, Vajkoczy P, Wick A, Harting I, Sahm F, von Deimling A, Bendszus M, Wick W, Platten M. Grassl N, et al. Among authors: tabatabai g. Neurol Res Pract. 2023 Oct 19;5(1):55. doi: 10.1186/s42466-023-00282-4. Neurol Res Pract. 2023. PMID: 37853454 Free PMC article.
The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
Weller J, Zeyen T, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Hau P, Seidel C, Goldbrunner R, Tabatabai G, Vatter H, Tzaridis T, Schneider M, Herrlinger U. Weller J, et al. Among authors: tabatabai g. J Neurooncol. 2023 Sep;164(3):749-755. doi: 10.1007/s11060-023-04470-9. Epub 2023 Oct 3. J Neurooncol. 2023. PMID: 37787906 Free PMC article.
172 results